Vitamin D differentially regulates B7.1 and B7.2 expression on human peripheral blood monocytes
The hormonal active form of vitamin D3, 1,25‐dihydroxyvitamin D3 (1,25(OH)2D3), inhibits (through an unknown mechanism) the ability of monocytes/macrophages to induce T‐cell activation. For T cells to be optimally activated, recognition of antigen/major histocompatibility complexes (MHC) by the T‐ce...
Gespeichert in:
Veröffentlicht in: | Immunology 1998-10, Vol.95 (2), p.272-277 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 277 |
---|---|
container_issue | 2 |
container_start_page | 272 |
container_title | Immunology |
container_volume | 95 |
creator | Clavreul, A D'hellencourt, C L Montero-Menei, C Potron, G Couez, D |
description | The hormonal active form of vitamin D3, 1,25‐dihydroxyvitamin D3 (1,25(OH)2D3), inhibits (through an unknown mechanism) the ability of monocytes/macrophages to induce T‐cell activation. For T cells to be optimally activated, recognition of antigen/major histocompatibility complexes (MHC) by the T‐cell receptor (TCR) must be accompanied by a second costimulatory signal. Considerable experimental data now suggest that this costimulatory signal is predominantly generated by B7.1 and/or B7.2 molecules, expressed on antigen‐presenting cells (APC), when engaged to their counter‐receptor, CD28, present on T cells. To determine whether the inhibitory effect of 1,25(OH)2D3 on monocytes/macrophages might involve modulation of the expression of B7.1 and B7.2 molecules, we analysed (by flow cytometry) the influence of 1,25(OH)2D3 and an analogue, KH 1060, on the expression of these two molecules at the surface of resting human peripheral blood monocytes. In parallel, we tested the effect of these two agents on human monocyte expression of cell‐surface markers (CD14 and CD4) and antigen‐presenting molecules (MHC class I and MHC class II). Our results showed that both 1,25(OH)2D3 and KH 1060 inhibited the basal expression of B7.2 in a dose‐ and time‐dependent manner, without affecting B7.1. Moreover, these two compounds increased CD14 and reduced MHC class II and CD4 expression. Furthermore, the effect of 1,25(OH)2D3 on B7 molecule expression in combination with lipopolysaccharide (LPS) or cytokines, including interleukin‐10 (IL‐10), interferon‐γ (IFN‐γ) and tumour necrosis factor‐α (TNF‐α), was studied. The 1,25(OH)2D3‐induced B7.2 down‐regulation was still detectable when monocytes were activated by IL‐10, IFN‐γ and TNF‐α but not with LPS. Moreover, the induction of B7.1 by TNF‐α was inhibited by addition of 1,25(OH)2D3. We conclude that the ability of 1,25(OH)2D3 to decrease B7.2 expression on human monocytes might contribute to its inhibitory effect on APC‐dependent T‐cell activation and to its immunosuppressive properties observed in autoimmune diseases and organ transplantation. |
doi_str_mv | 10.1046/j.1365-2567.1998.00588.x |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1364315</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>35171168</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5608-2f7bac864455f02d96e5483c09ae8e997b6e8a3d733784a17b5d78d1167a626d3</originalsourceid><addsrcrecordid>eNqNUluL1DAUDqKs4-pPEIIPgg-tuTQ3EGF3vezCLL6oryFtT3cytM2YTNeZf2_qDIPui0IgJznf950rQpiSkpJKvl2XlEtRMCFVSY3RJSFC63L3CC1OjsdoQQg1BdNEPEXPUlrnJydCnKEzo1lVablA9rvfusGP-ANufddBhHHrXd_vcYS7qXdbSPgyx8BubGeDYdhtIqTkw4jzWU2DG_EGot-sILoe130ILR7CGJp9Jj9HTzrXJ3hxvM_Rt08fv15dF8svn2-uLpZFIyTRBetU7Rotq0qIjrDWSBCV5g0xDjQYo2oJ2vFWca505aiqRat0S6lUTjLZ8nP0_qC7meoB2iaXkbOxm-gHF_c2OG__9ox-Ze_Cvc3tqjgVWeDNQWD1gHZ9sbTzH2GccGLUPc3Y18dgMfyYIG3t4FMDfe9GCFOyilDClZH_BFIp8tyYysBXD4DrMMUxd8zm8VYsl00ySB9ATQwpRehOeVJi57Ww67kcYefpzzxtf6-F3WXqyz_bcyIe9yD73x38P30P-__WtTe3t9ngvwBjP8Tq</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>199423370</pqid></control><display><type>article</type><title>Vitamin D differentially regulates B7.1 and B7.2 expression on human peripheral blood monocytes</title><source>MEDLINE</source><source>Wiley Online Library</source><source>Wiley Online Library Journals</source><source>PMC (PubMed Central)</source><source>EZB Free E-Journals</source><creator>Clavreul, A ; D'hellencourt, C L ; Montero-Menei, C ; Potron, G ; Couez, D</creator><creatorcontrib>Clavreul, A ; D'hellencourt, C L ; Montero-Menei, C ; Potron, G ; Couez, D</creatorcontrib><description>The hormonal active form of vitamin D3, 1,25‐dihydroxyvitamin D3 (1,25(OH)2D3), inhibits (through an unknown mechanism) the ability of monocytes/macrophages to induce T‐cell activation. For T cells to be optimally activated, recognition of antigen/major histocompatibility complexes (MHC) by the T‐cell receptor (TCR) must be accompanied by a second costimulatory signal. Considerable experimental data now suggest that this costimulatory signal is predominantly generated by B7.1 and/or B7.2 molecules, expressed on antigen‐presenting cells (APC), when engaged to their counter‐receptor, CD28, present on T cells. To determine whether the inhibitory effect of 1,25(OH)2D3 on monocytes/macrophages might involve modulation of the expression of B7.1 and B7.2 molecules, we analysed (by flow cytometry) the influence of 1,25(OH)2D3 and an analogue, KH 1060, on the expression of these two molecules at the surface of resting human peripheral blood monocytes. In parallel, we tested the effect of these two agents on human monocyte expression of cell‐surface markers (CD14 and CD4) and antigen‐presenting molecules (MHC class I and MHC class II). Our results showed that both 1,25(OH)2D3 and KH 1060 inhibited the basal expression of B7.2 in a dose‐ and time‐dependent manner, without affecting B7.1. Moreover, these two compounds increased CD14 and reduced MHC class II and CD4 expression. Furthermore, the effect of 1,25(OH)2D3 on B7 molecule expression in combination with lipopolysaccharide (LPS) or cytokines, including interleukin‐10 (IL‐10), interferon‐γ (IFN‐γ) and tumour necrosis factor‐α (TNF‐α), was studied. The 1,25(OH)2D3‐induced B7.2 down‐regulation was still detectable when monocytes were activated by IL‐10, IFN‐γ and TNF‐α but not with LPS. Moreover, the induction of B7.1 by TNF‐α was inhibited by addition of 1,25(OH)2D3. We conclude that the ability of 1,25(OH)2D3 to decrease B7.2 expression on human monocytes might contribute to its inhibitory effect on APC‐dependent T‐cell activation and to its immunosuppressive properties observed in autoimmune diseases and organ transplantation.</description><identifier>ISSN: 0019-2805</identifier><identifier>EISSN: 1365-2567</identifier><identifier>DOI: 10.1046/j.1365-2567.1998.00588.x</identifier><identifier>PMID: 9824486</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Antigen Presentation - drug effects ; Antigens, CD - metabolism ; B7-1 Antigen - metabolism ; B7-2 Antigen ; Calcitriol - analogs & derivatives ; Calcitriol - pharmacology ; CD4 Antigens - metabolism ; Cytokines - pharmacology ; Dose-Response Relationship, Drug ; Flow Cytometry ; Histocompatibility Antigens Class I - metabolism ; Histocompatibility Antigens Class II - metabolism ; Human health and pathology ; Humans ; Immunosuppressive Agents - pharmacology ; Life Sciences ; Lipopolysaccharide Receptors - metabolism ; Lipopolysaccharides - pharmacology ; Membrane Glycoproteins - metabolism ; Monocytes - drug effects ; Monocytes - immunology ; Time Factors</subject><ispartof>Immunology, 1998-10, Vol.95 (2), p.272-277</ispartof><rights>Copyright Blackwell Scientific Publications Ltd. Oct 1998</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5608-2f7bac864455f02d96e5483c09ae8e997b6e8a3d733784a17b5d78d1167a626d3</citedby><orcidid>0000-0002-1373-6987 ; 0000-0002-4477-8282</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1364315/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1364315/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,1411,1427,27901,27902,45551,46808,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9824486$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.univ-reunion.fr/hal-02303097$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Clavreul, A</creatorcontrib><creatorcontrib>D'hellencourt, C L</creatorcontrib><creatorcontrib>Montero-Menei, C</creatorcontrib><creatorcontrib>Potron, G</creatorcontrib><creatorcontrib>Couez, D</creatorcontrib><title>Vitamin D differentially regulates B7.1 and B7.2 expression on human peripheral blood monocytes</title><title>Immunology</title><addtitle>Immunology</addtitle><description>The hormonal active form of vitamin D3, 1,25‐dihydroxyvitamin D3 (1,25(OH)2D3), inhibits (through an unknown mechanism) the ability of monocytes/macrophages to induce T‐cell activation. For T cells to be optimally activated, recognition of antigen/major histocompatibility complexes (MHC) by the T‐cell receptor (TCR) must be accompanied by a second costimulatory signal. Considerable experimental data now suggest that this costimulatory signal is predominantly generated by B7.1 and/or B7.2 molecules, expressed on antigen‐presenting cells (APC), when engaged to their counter‐receptor, CD28, present on T cells. To determine whether the inhibitory effect of 1,25(OH)2D3 on monocytes/macrophages might involve modulation of the expression of B7.1 and B7.2 molecules, we analysed (by flow cytometry) the influence of 1,25(OH)2D3 and an analogue, KH 1060, on the expression of these two molecules at the surface of resting human peripheral blood monocytes. In parallel, we tested the effect of these two agents on human monocyte expression of cell‐surface markers (CD14 and CD4) and antigen‐presenting molecules (MHC class I and MHC class II). Our results showed that both 1,25(OH)2D3 and KH 1060 inhibited the basal expression of B7.2 in a dose‐ and time‐dependent manner, without affecting B7.1. Moreover, these two compounds increased CD14 and reduced MHC class II and CD4 expression. Furthermore, the effect of 1,25(OH)2D3 on B7 molecule expression in combination with lipopolysaccharide (LPS) or cytokines, including interleukin‐10 (IL‐10), interferon‐γ (IFN‐γ) and tumour necrosis factor‐α (TNF‐α), was studied. The 1,25(OH)2D3‐induced B7.2 down‐regulation was still detectable when monocytes were activated by IL‐10, IFN‐γ and TNF‐α but not with LPS. Moreover, the induction of B7.1 by TNF‐α was inhibited by addition of 1,25(OH)2D3. We conclude that the ability of 1,25(OH)2D3 to decrease B7.2 expression on human monocytes might contribute to its inhibitory effect on APC‐dependent T‐cell activation and to its immunosuppressive properties observed in autoimmune diseases and organ transplantation.</description><subject>Antigen Presentation - drug effects</subject><subject>Antigens, CD - metabolism</subject><subject>B7-1 Antigen - metabolism</subject><subject>B7-2 Antigen</subject><subject>Calcitriol - analogs & derivatives</subject><subject>Calcitriol - pharmacology</subject><subject>CD4 Antigens - metabolism</subject><subject>Cytokines - pharmacology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Flow Cytometry</subject><subject>Histocompatibility Antigens Class I - metabolism</subject><subject>Histocompatibility Antigens Class II - metabolism</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Life Sciences</subject><subject>Lipopolysaccharide Receptors - metabolism</subject><subject>Lipopolysaccharides - pharmacology</subject><subject>Membrane Glycoproteins - metabolism</subject><subject>Monocytes - drug effects</subject><subject>Monocytes - immunology</subject><subject>Time Factors</subject><issn>0019-2805</issn><issn>1365-2567</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUluL1DAUDqKs4-pPEIIPgg-tuTQ3EGF3vezCLL6oryFtT3cytM2YTNeZf2_qDIPui0IgJznf950rQpiSkpJKvl2XlEtRMCFVSY3RJSFC63L3CC1OjsdoQQg1BdNEPEXPUlrnJydCnKEzo1lVablA9rvfusGP-ANufddBhHHrXd_vcYS7qXdbSPgyx8BubGeDYdhtIqTkw4jzWU2DG_EGot-sILoe130ILR7CGJp9Jj9HTzrXJ3hxvM_Rt08fv15dF8svn2-uLpZFIyTRBetU7Rotq0qIjrDWSBCV5g0xDjQYo2oJ2vFWca505aiqRat0S6lUTjLZ8nP0_qC7meoB2iaXkbOxm-gHF_c2OG__9ox-Ze_Cvc3tqjgVWeDNQWD1gHZ9sbTzH2GccGLUPc3Y18dgMfyYIG3t4FMDfe9GCFOyilDClZH_BFIp8tyYysBXD4DrMMUxd8zm8VYsl00ySB9ATQwpRehOeVJi57Ww67kcYefpzzxtf6-F3WXqyz_bcyIe9yD73x38P30P-__WtTe3t9ngvwBjP8Tq</recordid><startdate>199810</startdate><enddate>199810</enddate><creator>Clavreul, A</creator><creator>D'hellencourt, C L</creator><creator>Montero-Menei, C</creator><creator>Potron, G</creator><creator>Couez, D</creator><general>Blackwell Science Ltd</general><general>Wiley Subscription Services, Inc</general><general>Wiley</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QR</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>1XC</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1373-6987</orcidid><orcidid>https://orcid.org/0000-0002-4477-8282</orcidid></search><sort><creationdate>199810</creationdate><title>Vitamin D differentially regulates B7.1 and B7.2 expression on human peripheral blood monocytes</title><author>Clavreul, A ; D'hellencourt, C L ; Montero-Menei, C ; Potron, G ; Couez, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5608-2f7bac864455f02d96e5483c09ae8e997b6e8a3d733784a17b5d78d1167a626d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Antigen Presentation - drug effects</topic><topic>Antigens, CD - metabolism</topic><topic>B7-1 Antigen - metabolism</topic><topic>B7-2 Antigen</topic><topic>Calcitriol - analogs & derivatives</topic><topic>Calcitriol - pharmacology</topic><topic>CD4 Antigens - metabolism</topic><topic>Cytokines - pharmacology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Flow Cytometry</topic><topic>Histocompatibility Antigens Class I - metabolism</topic><topic>Histocompatibility Antigens Class II - metabolism</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Life Sciences</topic><topic>Lipopolysaccharide Receptors - metabolism</topic><topic>Lipopolysaccharides - pharmacology</topic><topic>Membrane Glycoproteins - metabolism</topic><topic>Monocytes - drug effects</topic><topic>Monocytes - immunology</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Clavreul, A</creatorcontrib><creatorcontrib>D'hellencourt, C L</creatorcontrib><creatorcontrib>Montero-Menei, C</creatorcontrib><creatorcontrib>Potron, G</creatorcontrib><creatorcontrib>Couez, D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Clavreul, A</au><au>D'hellencourt, C L</au><au>Montero-Menei, C</au><au>Potron, G</au><au>Couez, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vitamin D differentially regulates B7.1 and B7.2 expression on human peripheral blood monocytes</atitle><jtitle>Immunology</jtitle><addtitle>Immunology</addtitle><date>1998-10</date><risdate>1998</risdate><volume>95</volume><issue>2</issue><spage>272</spage><epage>277</epage><pages>272-277</pages><issn>0019-2805</issn><eissn>1365-2567</eissn><abstract>The hormonal active form of vitamin D3, 1,25‐dihydroxyvitamin D3 (1,25(OH)2D3), inhibits (through an unknown mechanism) the ability of monocytes/macrophages to induce T‐cell activation. For T cells to be optimally activated, recognition of antigen/major histocompatibility complexes (MHC) by the T‐cell receptor (TCR) must be accompanied by a second costimulatory signal. Considerable experimental data now suggest that this costimulatory signal is predominantly generated by B7.1 and/or B7.2 molecules, expressed on antigen‐presenting cells (APC), when engaged to their counter‐receptor, CD28, present on T cells. To determine whether the inhibitory effect of 1,25(OH)2D3 on monocytes/macrophages might involve modulation of the expression of B7.1 and B7.2 molecules, we analysed (by flow cytometry) the influence of 1,25(OH)2D3 and an analogue, KH 1060, on the expression of these two molecules at the surface of resting human peripheral blood monocytes. In parallel, we tested the effect of these two agents on human monocyte expression of cell‐surface markers (CD14 and CD4) and antigen‐presenting molecules (MHC class I and MHC class II). Our results showed that both 1,25(OH)2D3 and KH 1060 inhibited the basal expression of B7.2 in a dose‐ and time‐dependent manner, without affecting B7.1. Moreover, these two compounds increased CD14 and reduced MHC class II and CD4 expression. Furthermore, the effect of 1,25(OH)2D3 on B7 molecule expression in combination with lipopolysaccharide (LPS) or cytokines, including interleukin‐10 (IL‐10), interferon‐γ (IFN‐γ) and tumour necrosis factor‐α (TNF‐α), was studied. The 1,25(OH)2D3‐induced B7.2 down‐regulation was still detectable when monocytes were activated by IL‐10, IFN‐γ and TNF‐α but not with LPS. Moreover, the induction of B7.1 by TNF‐α was inhibited by addition of 1,25(OH)2D3. We conclude that the ability of 1,25(OH)2D3 to decrease B7.2 expression on human monocytes might contribute to its inhibitory effect on APC‐dependent T‐cell activation and to its immunosuppressive properties observed in autoimmune diseases and organ transplantation.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>9824486</pmid><doi>10.1046/j.1365-2567.1998.00588.x</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-1373-6987</orcidid><orcidid>https://orcid.org/0000-0002-4477-8282</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0019-2805 |
ispartof | Immunology, 1998-10, Vol.95 (2), p.272-277 |
issn | 0019-2805 1365-2567 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1364315 |
source | MEDLINE; Wiley Online Library; Wiley Online Library Journals; PMC (PubMed Central); EZB Free E-Journals |
subjects | Antigen Presentation - drug effects Antigens, CD - metabolism B7-1 Antigen - metabolism B7-2 Antigen Calcitriol - analogs & derivatives Calcitriol - pharmacology CD4 Antigens - metabolism Cytokines - pharmacology Dose-Response Relationship, Drug Flow Cytometry Histocompatibility Antigens Class I - metabolism Histocompatibility Antigens Class II - metabolism Human health and pathology Humans Immunosuppressive Agents - pharmacology Life Sciences Lipopolysaccharide Receptors - metabolism Lipopolysaccharides - pharmacology Membrane Glycoproteins - metabolism Monocytes - drug effects Monocytes - immunology Time Factors |
title | Vitamin D differentially regulates B7.1 and B7.2 expression on human peripheral blood monocytes |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T17%3A08%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vitamin%20D%20differentially%20regulates%20B7.1%20and%20B7.2%20expression%20on%20human%20peripheral%20blood%20monocytes&rft.jtitle=Immunology&rft.au=Clavreul,%20A&rft.date=1998-10&rft.volume=95&rft.issue=2&rft.spage=272&rft.epage=277&rft.pages=272-277&rft.issn=0019-2805&rft.eissn=1365-2567&rft_id=info:doi/10.1046/j.1365-2567.1998.00588.x&rft_dat=%3Cproquest_pubme%3E35171168%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=199423370&rft_id=info:pmid/9824486&rfr_iscdi=true |